LENZ Therapeutics, Inc. (LENZ)
5.96
+0.13
(+2.23%)
USD |
NASDAQ |
Sep 04, 16:00
5.965
0.00 (0.00%)
After-Hours: 20:00
LENZ Therapeutics Research and Development Expense (Quarterly) : 0.00 for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 3.791M |
| June 30, 2025 | 9.061M |
| March 31, 2025 | 5.818M |
| December 31, 2024 | 5.868M |
| September 30, 2024 | 6.451M |
| June 30, 2024 | 6.945M |
| March 31, 2024 | 10.54M |
| December 31, 2023 | 19.54M |
| September 30, 2023 | 17.00M |
| June 30, 2023 | 12.64M |
| Date | Value |
|---|---|
| March 31, 2023 | 10.32M |
| December 31, 2022 | 16.24M |
| September 30, 2022 | 16.13M |
| June 30, 2022 | 17.78M |
| March 31, 2022 | 18.25M |
| December 31, 2021 | 11.20M |
| September 30, 2021 | 8.683M |
| June 30, 2021 | 12.67M |
| March 31, 2021 | 5.377M |
| December 31, 2020 | 6.39M |
| September 30, 2020 | 2.31M |
| June 30, 2020 | 0.423M |
| March 31, 2020 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Impact BioMedical, Inc. | 0.076M |
| Enveric Biosciences, Inc. | 1.355M |
| Ocular Therapeutix, Inc. | 54.14M |
| Liquidia Corp. | 16.88M |
| Aquestive Therapeutics, Inc. | 3.962M |